ArticleJournal of advanced research2026
Effects of general anesthetics on seizure termination, mortality, and neurological prognosis in a rat model of pediatric refractory status epilepticus: A comparative randomized controlled study.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRefractory status epilepticus (RSE) is a serious neurological emergency in children associated with significant mortality and morbidity. General anesthetics (GAs) are routinely used to treat RSE. However, the optimal selection of GAs for pediatric RSE remains unknown.
objectiveWe aimed to identify the optimal agent by comparing the efficacy and safety of different GAs in a rat model of RSE.
methodsSprague-Dawley rats at postnatal day 20 were subjected to lithium-pilocarpine-induced SE. Animals that developed RSE (pharmacoresistant to the first- and second-line therapies) were randomized to receive one of five GAs (midazolam, propofol, dexmedetomidine, esketamine, or sevoflurane) as the third-line therapy or vehicles. The latency to SE termination (time from the initiation of GAs to SE termination) and 24-hour mortality were assessed. On Day 5 following SE, a series of behavioral tests were performed to evaluate the behavior and cognition.
resultsAll five GAs effectively terminated the RSE, with propofol and sevoflurane having the shortest latencies to SE termination. GAs significantly improved survival after the complete termination of SE. Additionally, GAs reduced the cognitive deficits caused by SE, especially episodic memory, without affecting the behavioral abnormalities. Finally, we proposed a multi-dimensional model that integrated the efficacy, safety, and effect of GAs on neurological prognosis, suggesting that sevoflurane might be the optimal treatment.
conclusionOur study showed that treatment with GAs effectively terminated RSE and improved survival and short-term cognition. Our proposed model suggests that volatile anesthetics may be the optimal choice for treating RSE. These results may be used to inform the design of comparative clinical trials of GAs for RSE in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.